肿瘤治疗新靶点：碱性成纤维细胞生长因子及其受体信号

摘要: 碱性成纤维细胞生长因子（bFGF）是一个促细胞分裂、增殖及血管生成的多肽生长因子，肿瘤组织中bFGF及其受体过度表达为抗肿瘤治疗提供潜在靶目标，研制靶向性抗bFGF抗体、FGFR抑制剂等抑制肿瘤细胞增殖和新血管形成，阻断肿瘤生长的营养和转移途径，成为抗肿瘤热点。本文就bFGF及其受体信号在肿瘤的发生、发展和转移中的作用及临床转化研究进行综述。
- bFGF /
- FGFR /
- 信号转导 /
- 临床转化研究
Abstract: Basic fibroblast growth factor (bFGF) is a kind of polypeptide that serves an important function in mitogen, proliferation, and angiogenesis. bFGF is a potential anti-cancer therapy target and its receptor is highly expressed in tumor tissue. Antitumor drugs such as anti-bFGF antibody and FGFR antagonists are being developed to block tumor growth and metastasis. In this paper, bFGF and its receptor signaling pathway in tumor development and metastasis is investigated, and clinical translational research is reviewed.
- bFGF /
- FGFR /
- signal transduction /
- clinical translational research

HTML全文

表 1 基于bFGF/FGFR1信号通路的肿瘤靶向药物

Table 1. Current anticancer agents of bFGF/FGFR-targeting therapies

参考文献(38)

[1]	Kottakis F, Polytarchou C, Foltopoulou P, et al. FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway[J]. Mol Cell, 2011, 43(2):285-298. doi: 10.1016/j.molcel.2011.06.020
[2]	Villegas SN, Canham M, Brickman JM. FGF signalling as a mediator of lineage transitions--evidence from embryonic stem cell differentiation[J]. J Cell Biochem, 2010, 110(1):10-20. http://cn.bing.com/academic/profile?id=88dac933a0615c46466e6bcd7ba50f55&encoded=0&v=paper_preview&mkt=zh-cn
[3]	Kimelman D, Kirschner M. Synergistic induction of mesoderm by FGF and TGF-beta and the identification of an mRNA coding for FGF in the early Xenopus embryo[J]. Cell, 1987, 51(5):869-877. doi: 10.1016/0092-8674(87)90110-3
[4]	Knights V, Cook SJ. De-regulated FGF receptors as therapeutic targets in cancer[J]. Pharmacol Ther, 2010, 125(1):105-117. http://cn.bing.com/academic/profile?id=399806e311d0243b58848f782677b6dd&encoded=0&v=paper_preview&mkt=zh-cn
[5]	Liang XJ, Yuan L, Hu J, et al. Phosphomannopentaose sulfate (PI-88) suppresses angiogenesis by downregulating heparanase and vascular endothelial growth factor in an oxygen-induced retinal neovascularization animal model[J]. Mol Vis, 2012, 18:1649-1657. http://cn.bing.com/academic/profile?id=420dc1817d50c1d8a6cb01989a003fe3&encoded=0&v=paper_preview&mkt=zh-cn
[6]	Ori A, Wilkinson MC, Fernig DG. The heparanome and regulation of cell function: structures, functions and challenges[J]. Front Biosci, 2008, 13:4309-4338. http://cn.bing.com/academic/profile?id=e5af521946dfb1bdf624499d5eabfcbb&encoded=0&v=paper_preview&mkt=zh-cn
[7]	Lin X, Buff EM, Perrimon N, et al. Heparan sulfate proteoglycans are essential for FGF receptor signaling during Drosophila embryonic development[J]. Development, 1999, 126(17):3715-3723. https://www.ncbi.nlm.nih.gov/pubmed/10433902
[8]	Schlessinger J. Common and distinct elements in cellular signaling via EGF and FGF receptors[J]. Science, 2004, 306(5701):1506-1507. doi: 10.1126/science.1105396
[9]	Cao R, Brakenhielm E, Pawliuk R, et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2[J]. Nat Med, 2003, 9(5):604-613. doi: 10.1038/nm848
[10]	张志华, 刘鹏, 王丽红, 等. bFGF表达对裸鼠白血病移植瘤血管新生影响的研究[J].中国肿瘤临床, 2013, 40(14):821-823. Zhang ZH, Liu P, Wang LH, et al. Effects of bFGF expression on the angiogenesis of a leukemia cell line transplanted into nude mice[J]. Chin J Clin Oncol, 2013, 40(14):821-823.
[11]	Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer[J]. Nat Rev Cancer, 2010, 10(2):116-129. doi: 10.1038/nrc2780
[12]	Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors[J]. Cytokine Growth Factor Rev, 2005, 16(2):139-149. doi: 10.1016/j.cytogfr.2005.01.001
[13]	Farhat FS, Tfayli A, Fakhruddin N, et al. Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer[J]. Crit Rev Oncol Hematol, 2012, 84(2):149-160. https://www.ncbi.nlm.nih.gov/pubmed/22494932
[14]	Wang Y, Becker D. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth[J]. Nat Med, 1997, 3(8):887-893. doi: 10.1038/nm0897-887
[15]	Coldren CD, Helfrich BA, Witta SE, et al. Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines[J]. Mol Cancer Res, 2006, 4(8):521-528. doi: 10.1158/1541-7786.MCR-06-0095
[16]	Casanovas O, Hicklin DJ, Bergers G, et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors[J]. Cancer Cell, 2005, 8(4):299-309. doi: 10.1016/j.ccr.2005.09.005
[17]	Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes[J]. Nature, 2007, 446(7132):153-158. doi: 10.1038/nature05610
[18]	Rand V, Huang J, Stockwell T, et al. Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas[J]. Proc Natl Acad Sci USA, 2005, 102(40):14344-14349. doi: 10.1073/pnas.0507200102
[19]	Gorringe KL, Jacobs S, Thompson ER, et al. High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications[J]. Clin Cancer Res, 2007, 13(16):4731-4739. doi: 10.1158/1078-0432.CCR-07-0502
[20]	Xiao S, Nalabolu SR, Aster JC, et al. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome[J]. Nat Genet, 1998, 18(11):84-87.
[21]	Lindorfer MA, Wiestner A, Zent CS, et al. Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies[J]? Oncoimmunology, 2012, 1(6):959-961.
[22]	Massoglia SL, Kenney JS, Gospodarowicz DJ. Characterization of murine monoclonal antibodies directed against basic fibroblast growth factor[J]. J Cell Physiol, 1987, 132(3):531-537. doi: 10.1002/jcp.1041320316
[23]	向军俭, 靳英杰, 黄红亮, 等.人bFGF单克隆抗体的制备及MabF7对黑色素瘤B16的体外抗瘤效应[J].中华肿瘤防治杂志, 2008, 15(1):19-22. doi: 10.3969/j.issn.1673-5269.2008.01.006 Xiang JJ, Jin YJ, Huang HL, et al. Production preparation of human bFGF monoclonal antibodies and their antitumor activities with MabF7 on melanoma cells B16in vitro[J]. Chin J Cancer Prev Treat, 2008, 15(1):19-22. doi: 10.3969/j.issn.1673-5269.2008.01.006
[24]	曾世彬, 徐萌, 潘兰红, 等.bFGF单抗联合放疗对小鼠B16移植瘤的协同作用[J].中国肿瘤生物治疗杂志, 18(2):175-180. doi: 10.3872/j.issn.1007-385X.2011.02.011 Zeng ShB, Xu M, Pan LH, et al. Synergistic inhibitory effects of bFGF monoclonal antibody combined with radiotherapy on B16-transplanted tumors in mice[J]. Chin J Cancer Biother, 2011, 18(2):175-180. doi: 10.3872/j.issn.1007-385X.2011.02.011
[25]	陈文慧, 徐萌, 杜超超, 等.碱性成纤维细胞生长因子单克隆抗体通过P-糖蛋白逆转乳腺癌MCF-7/ADM细胞多药耐药性的分子机制[J].肿瘤, 2013, 33(1):8-14. doi: 10.3781/j.issn.1000-7431.2013.01.002 Chen WH, Xu M, Du CC, et al. Molecular mechanism of reversal effect of monoclonal antibody to basic fibroblast growth factor-mediated expression of P-glycoprotein on multiple drug resistance in adriamycin-resistant human breast cancer cell line MCF-7/ADM. [J]. Tumor, 2013, 33(1):8-14. doi: 10.3781/j.issn.1000-7431.2013.01.002
[26]	Harding TC, Long L, Palencia S, et al. Blockade of Nonhormonal Fibroblast Growth Factors by FP-1039 Inhibits Growth of Multiple Types of Cancer[J]. Sci Transl Med, 2013, 5(178):178ra39. http://cn.bing.com/academic/profile?id=fd1aaa2450cfc5f01efac4a3f0c19e70&encoded=0&v=paper_preview&mkt=zh-cn
[27]	Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome[J]. Science, 2002, 298(5600):1912-1934. doi: 10.1126/science.1075762
[28]	Musib L, Choo E, Deng Y, et al. Absolute Bioavailability and Effect of Formulation Change, Food, or Elevated pH with Rabeprazole on Cobimetinib Absorption in Healthy Subjects[J]. Mol Pharm, 2013, 10(11):4046-4054. doi: 10.1021/mp400383x
[29]	Ren M, Hong M, Liu G, et al. Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1[J]. Oncol Rep, 2013, 29(6):2181-2190. doi: 10.3892/or.2013.2386
[30]	Diamond JR, Eckhardt SG, Tan AC, et al. Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models[J]. Clin Cancer Res: an official journal of the American Association for Cancer Res, 2013, 19(1):291-303. doi: 10.1158/1078-0432.CCR-12-1611
[31]	Ohta M, Kawabata T, Yamamoto M, et al. TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model[J]. Surg Today, 2009, 39(12):1046-1053. doi: 10.1007/s00595-009-4020-y
[32]	Festino L, Fabozzi A, Manzo A, et al. Critical appraisal of the use of regorafenib in the management of colorectal cancer[J]. Cancer Manag Res, 2013, 5:49-55.
[33]	Antoniu SA. Nintedanib (BIBF 1120) for IPF: a tomorrow therapy? [J]. Multidiscip Respir Med, 2012, 7(1):41. doi: 10.1186/2049-6958-7-41
[34]	Jang MH, Kim EJ, Choi Y, et al. FGFR1 is amplified during the progression of in situ to invasive breast carcinoma[J]. Breast Cancer Res, 2012, 14(4):R115. doi: 10.1186/bcr3239
[35]	Gavine PR, Mooney L, Kilgour E, et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family[J]. Cancer Res, 2012, 72(8):2045-2056. doi: 10.1158/0008-5472.CAN-11-3034
[36]	Konecny GE, Kolarova T, O'Brien NA, et al. Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells[J]. Mol Cancer Ther, 2013, 12(5):632-642. doi: 10.1158/1535-7163.MCT-12-0999
[37]	Zhao G, Li WY, Chen D, et al. A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models[J]. Mol Cancer Ther, 2011, 10(11):2200-2210. doi: 10.1158/1535-7163.MCT-11-0306
[38]	Loi S, Haibe-Kains B, Majjaj S, et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer[J]. Proc Nat Acad Sci USA, 2010, 107(22):10208-10213. doi: 10.1073/pnas.0907011107